## **Supplementary Material**

## Metabolomics analysis reveals metabolic changes associated with trans-resveratrol treatment in experimental cryptorchidism mice

Siqiang Li<sup>A,\*</sup>, Yun Li<sup>A,B,\*</sup>, Fujia Chen<sup>A</sup>, Yurong Yang<sup>A</sup>, Li Song<sup>A</sup>, Chaoying Liu<sup>A,B</sup>, Baogen Wang<sup>A</sup>, Yuanhong Xu<sup>A</sup>, Mingguang Shao<sup>A</sup> and Enzhong Li<sup>A,C</sup>

<sup>A</sup>School of Biological and Food Processing Engineering, Huanghuai University, Zhumadian, China.

<sup>B</sup>Zhumadian Academy of Industry Innovation and Development, Huanghuai University, Zhumadian, China.

<sup>c</sup>Corresponding author. Email: enzhongli@163.com

**Fig. S1.** PCA score plot of QC and metabolites collected from the control, cryptorchid, and RSV-treated cryptorchid group mice in both the (A) ESI+ and (B) ESI- modes.

**Fig. S2.** Multivariate statistical analyses of metabolites in the testis fragments of mice in the cryptorchid group versus the control group.

**Fig. S3.** Multivariate statistical analyses of metabolites in the testis fragments of mice in the RSV-treated cryptorchid group versus the cryptorchid group.

**Fig. S4.** Multivariate statistical analyses of metabolites in the testis fragments of mice in the RSV-treated cryptorchid group versus the control group.

**Fig. S5.** Histogram showed the common and unique differential metabolites in the control, cryptorchid, and RSV-treated cryptorchid groups.

**Fig. S6.** Differential metabolic pathways (Top 20) for cryptorchid group versus control group in ESI+ (A) and ESI– (B) modes.

**Fig. S7.** Differential metabolic pathways for RSV-treated cryptorchid group versus cryptorchid group in ESI+ (A) and ESI- (B) modes.

\*These authors contributed equally to this work.



Fig. S1. PCA score plot of QC and metabolites collected from the control, cryptorchid, and RSV-treated cryptorchid group mice in both the (A) ESI+ and (B) ESI- modes.



**Fig. S2.** Multivariate statistical analyses of metabolites in the testis fragments of mice in the cryptorchid group versus the control group. PCA score plots in the (A) ESI+ mode and (B) ESI- mode. PLS-DA score plots in the (C) ESI+ mode and (D) ESI- mode. Response sequencing check diagrams of PLS-DA models in the (E) ESI+ mode and (F) ESI- mode.



Fig. S3. Multivariate statistical analyses of metabolites in the testis fragments of mice in the RSV-treated cryptorchid group versus the cryptorchid group. PCA score plots in the (A) ESI+ mode and (B) ESI- mode. PLS-DA score plots in the (C) ESI+ mode and (D): ESI- mode. Response sequencing check diagrams of PLS-DA models in the (E) ESI+ mode and (F) ESI- mode.



Fig. S4. Multivariate statistical analyses of metabolites in the testis fragments of mice in the RSV-treated cryptorchid group versus the control group. PCA score plots in the (A) ESI+ mode and (B) ESI- mode. PLS-DA score plots in the (C) ESI+ mode and (D) ESI- mode. Response sequencing check diagrams of PLS-DA models in the (E) ESI+ mode and (F) ESI- mode.



Fig. S5. Histogram showed the common and unique differential metabolites in the control, cryptorchid, and RSV-treated cryptorchid groups. Each value is mean  $\pm$  s.d. \*P < 0.05, \*\*P < 0.01, and \*\*\*P < 0.001.

(Fig. S5. continued over page)



Fig. S5. cont.





Fig. S6. Differential metabolic pathways (Top 20) for cryptorchid group versus control group in ESI+ (A) and ESI-(B) modes.



Fig. S7. Differential metabolic pathways for RSV-treated cryptorchid group versus cryptorchid group in ESI+(A) and ESI-(B) modes.